Currently, although there is no study that specifically associates EGFR TKIs with chemotherapy in advanced NSCLC with combined EGFR and TP53 mutations, studies are being conducted comparing monotherapy with EGFR inhibitors to the combined therapy of EGFR and chemotherapy [33,34]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.